Pirfact 267 mg Tablet 10's
₹198*
MRP ₹220
10% off
₹187*
MRP ₹220
15% CB
₹33 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Pirfact 267 mg Tablet is used to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is an irreversible disease that is marked by a progressive decline in lung function. The tissues in the lungs become swollen and scarred over time, which makes it difficult to breathe deeply. The scarring makes it hard for the lungs to work properly.
Pirfact 267 mg Tablet contains ‘Pirfenidone’, which helps reduce scarring and swelling in the lungs by decreasing the release/activity of naturally occurring growth factors in the body, thereby helping you breathe better. Pirfact 267 mg Tablet helps in slowing down the progress of idiopathic pulmonary fibrosis.
In some cases, you may experience certain common side effects such as nausea, tiredness, diarrhoea, indigestion, loss of appetite, headache, and photosensitivity. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if you experience these side effects persistently.
Consult your doctor before taking Pirfact 267 mg Tablet if you are pregnant or breastfeeding. Pirfact 267 mg Tablet may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Pirfact 267 mg Tablet as it could lead to increased dizziness. Pirfact 267 mg Tablet is not recommended for children below 18 years as safety and effectiveness have not been established. Keep your doctor informed about your health condition and medicines to rule out any side effects.
Pirfact 267 mg Tablet is an anti-fibrotic medicine used to treat idiopathic pulmonary fibrosis (IPF) in adults. Pirfact 267 mg Tablet can help effectively slow the rate of lung function decline by 50%. Pirfact 267 mg Tablet helps reduce the scarring and swelling in the lungs by decreasing the release/activity of naturally occurring growth factors in the body, thereby helping you breathe better. Pirfact 267 mg Tablet helps in slowing down the progress of idiopathic pulmonary fibrosis.
Do not take Pirfact 267 mg Tablet if you are allergic to any of its components; if you have a severe or end-stage liver impairment or kidney disease requiring dialysis; if you are taking fluvoxamine (anti-depressant). Inform your doctor if you are taking any medicines that might make you photosensitive, if you smoke or have kidney or liver problems. Consult your doctor before taking Pirfact 267 mg Tablet if you are pregnant or breastfeeding. Pirfact 267 mg Tablet may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Pirfact 267 mg Tablet as it could lead to increased dizziness. Pirfact 267 mg Tablet is not recommended for children below 18 years as safety and effectiveness have not been established.
Drug-Drug Interactions: Pirfact 267 mg Tablet may interact with an anti-depressant (fluvoxamine), antibiotics (ciprofloxacin, enoxacin, rifampicin), antiarrhythmic (amiodarone, propafenone), antacid (omeprazole).
Drug-Food Interactions: Avoid grapefruit juice and chargrilled meats.
Drug-Disease Interactions: Inform your doctor if you have severe hepatic problems or end-stage renal impairment requiring dialysis.
Watch out for triggers that make the cough worse, such as smoke, foods, air-conditioning, high altitude, etc.
Exercise moderately. Eat healthily.
Follow the pulmonary rehabilitation program. It includes exercise, disease education, and group therapy.
Quit smoking.
Get ample rest.
Include green leafy vegetables, sweet potatoes, broccoli, tomatoes, carrots, mangoes, citrus fruits, berries, and cocoa.
Lean proteins such as fish, meat, and poultry are the best.
Hydration is important. Drink plenty of water, herbal tea, and fruit juices.
Avoid processed and refined foods.
Your doctor may advise liver function tests prior to the start of the treatment.
Regular blood tests are advised at the start of treatment with Pirfact 267 mg Tablet and monthly for every 6 months, and then for every 3 months thereafter to check the liver functioning.
Idiopathic pulmonary fibrosis (IPF): Idiopathic pulmonary fibrosis belongs to a group of interstitial lung diseases. It is an irreversible chronic disease marked by a progressive decline in lung function. The tissues in the lungs become inflamed and scarred over time, which makes it difficult to breathe properly. The scar tissue, known as fibrosis, becomes thick /stiff over time, making it hard for the lungs to work efficiently. This causes decreased lung function, which leads to increased breathlessness and coughing. Breathing difficulties can lead to other medical problems. Symptoms of IPF are shortness of breath, persistent dry cough, loss of appetite, weight loss, and rounded and widened tips of the fingers and toes.
Alcohol
Caution
It is not known if alcohol interacts with Pirfact 267 mg Tablet . However, avoid consumption of alcohol while taking Pirfact 267 mg Tablet as it may cause increased dizziness.
Pregnancy
Caution
Please consult your doctor if you have any concerns regarding this; your doctor will prescribe only if the benefits outweigh the risks.
Breast Feeding
Caution
Consult your doctor if you are breastfeeding; your doctor will decide whether Pirfact 267 mg Tablet can be taken by breastfeeding mothers or not.
Driving
Caution
Pirfact 267 mg Tablet might cause dizziness and tiredness. Drive or operate machinery only if you are alert.
Liver
Caution
Dose adjustment may be needed. Please consult your doctor if you have a liver impairment or any concerns regarding this. Pirfact 267 mg Tablet is not recommended for patients with severe hepatic impairment.
Kidney
Caution
Dose adjustment may be needed. Please consult your doctor if you have kidney impairment or any concerns. Pirfact 267 mg Tablet is not recommended for patients with an end-stage renal disease requiring dialysis.
Children
Unsafe
Pirfact 267 mg Tablet is not recommended for children below 18years as the safety and effectiveness has not been established.
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Product Substitutes